S
Sheri Shirazian
Publications - 3
Citations - 2735
Sheri Shirazian is an academic researcher. The author has contributed to research in topics: Receptor tyrosine kinase & Platelet-derived growth factor receptor. The author has an hindex of 3, co-authored 3 publications receiving 2647 citations.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Li Sun,Chris Liang,Sheri Shirazian,Yong Zhou,Todd W. Miller,Jean Cui,Juri Y Fukuda,Ji-Yu Chu,Asaad S. Nematalla,Xueyan Wang,Hui Chen,Anand Sistla,Tony C Luu,Flora Tang,James Wei,Cho Tang +15 more
TL;DR: 5-Fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyros
Journal Article
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Martin Sattler,Yuri B. Pride,Patrick C. Ma,Jessica L. Gramlich,Stephanie C. Chu,Laura A. Quinnan,Sheri Shirazian,Congxin Liang,Klaus Podar,James G. Christensen,Ravi Salgia +10 more
TL;DR: The characterization of SU11274 as an effective inhibitor of Met tyrosine kinase activity illustrates the potential of targeting for Met therapeutic use in cancers associated with activated forms of this kinase.